Background {#s1}
==========

At the end of Sixties, three skilled scientists from the University of California San Francisco Medical Center first described and characterized the enzymatic activity of heme oxygenase (HO), a microsomal enzyme catalyzing the oxidative cleavage of hemoproteins' prosthetic group in equimolar amounts of ferrous iron, carbon monoxide (CO) and biliverdin (BV) ([@B100]; [@B101]). Following this initial description of the enzymatic activity, there were many other findings, including the inducible and constitutive nature of HO (HO-1 and HO-2, respectively), as well as the full characterization of biliverdin reductase (BVR), a cytosolic enzyme that works in combination with HO and reduces BV into bilirubin (BR). A significant contribution to these discoveries was provided by Mahin Maines and her research group \[see ([@B58]; [@B59]; [@B60]) and references therein\] who, recently, have deepened the field by describing pleiotropic effects of BVR in terms of modulation of numerous cytoprotective signaling pathways \[see ([@B61]; [@B42]; [@B29]) and references therein\].

Following these observations, the HO/BVR system has been studied worldwide by scientists who have gradually discovered its enormous potential. Just to give an idea of the attention aroused, suffice it to say that since 1969, more than 15300 papers have been published containing the keyword "heme oxygenase" (source: PubMed, accessed on August 8, 2019), while, concerning "biliverdin reductase," the first studies appeared in 1965 reaching, to date, more than 450 papers (source: PubMed, accessed on August 8, 2019). The numbers mentioned so far have been achieved thanks to the many studies that have described the involvement of the HO/BVR system in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), atherosclerosis and other cardiovascular disorders, kidney diseases, diabetes, etc. The molecular mechanisms through which the HO-1/BVR system exerts neuroprotective effects mainly depends on the down-stream effectors CO and BR. In the nervous system, CO has been shown to modulate synaptic plasticity, neuropeptide secretion, and neurogenesis ([@B106]; [@B74]; [@B67]; [@B19]), whereas BR interacts with reactive oxygen species (ROS), reactive nitrogen species (RNS) and nitric oxide (NO) to prevent neurotoxicity due to free radical injury ([@B65]; [@B66]; [@B8]; [@B63]). While the antioxidant and cytoprotective effects of the HO/BVR system and its by-products have been extensively described in literature, scarce attention has been dedicated to a critical examination of their potentially toxic effects. Our research group has contributed to this field by describing the cytotoxic effects of CO either through the inhibition of the stress axis under pro-inflammatory conditions or production of pro-inflammatory prostaglandins (PG) (e.g., PGE2) in rat hypothalamus \[see ([@B70]; [@B69]; [@B67]) and references therein\]. Moreover, we have also explored the cytoprotective *vs* cytotoxic effects of the interaction between BR and NO \[see ([@B68]; [@B62]) and references therein; ([@B8])\]. Hyman Schipper's group, instead, decisively contributed to the discovery of the neurotoxic role of HO-derived iron in mitochondrial dysfunctions and in the genesis of oxidative stress-induced damage in neurons and glial cells \[see ([@B91]; [@B93]; [@B92]) and references therein\]. Finally, Shigeki Shibahara and Kazuhiko Igarashi, with collaborators, discovered the importance of HO-1 gene repression, through the transcription factor Bach1, to reduce cellular toxic effects due to iron and CO accumulation as in the case of strong and long-lasting pro-oxidant conditions ([@B97]; [@B98]; [@B36]). These findings contributed to increase the awareness of the risks associated with the uncontrolled activation of the HO/BVR system.

A particularly detailed aspect, starting from the early 2000s, was the interaction between HO-1 and products of herbal origin, and caffeic acid derivatives were the first to be studied ([@B90]); only later, many studies have appeared in the literature concerning the ability of several other herbal products to induce HO-1 ([@B73]; [@B71]; [@B26]; [@B72]). However, as detailed below, the up-regulation of HO-1 by herb-derived nutritional supplements is claimed as a beneficial mechanism through which they exert neuroprotective outcomes. In this regard, however, it is worth underlining how not always the fine involvement of HO-1 in the claimed neuroprotective effects of herbal products has been studied, but frequently HO-1 induction has been considered rather as a mere biomarker of activation of the cell stress response. In our opinion, the aspects that are still weak and are worth investigating, with regard to the effects of herbal products through HO-1 up-regulation, are the following: (i) the correlation between the dose/concentration of herbal product capable of inducing HO-1 *in vitro* and its effective concentration in the target organ within *in vivo* studies; (ii) the extent and duration of HO-1 induction, considering that, as previously mentioned, the accumulation of products, such as iron and CO can become toxic to cells, (iii) loss of specificity of the obtained results, as nearly all the studied herbal products induced HO-1 and (iv) the reduced number of studies that evaluated the BVR modulation, through herbal products.

The purpose of this review is to provide a critical overview of the potential therapeutic role of ferulic acid, *Ginkgo biloba*, and resveratrol *via* the modulation of the HO/BVR system; the reason why the attention has been focused on these herbal products depends on the consistent number of articles published on this topic through the years strong enough to substantiate a potential interest towards clinics. The safety profile of ferulic acid, *G. biloba*, and resveratrol has been also evaluated with the purpose to provide a complete overview of the risk/benefit balance of a chronic supplementation with these agents.

Ferulic Acid {#s2}
============

Ferulic acid {\[(E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid)\], FA, [**Figure 1**](#f1){ref-type="fig"}} belongs to the family of phenolic acids and is highly abundant in fruits and vegetables. Furthermore, FA is also a component of Chinese medicinal herbs, such as *Angelica sinensis*, *Cimicifuga racemosa*, and *Ligusticum chuangxiong*. The main pharmacokinetic parameters of FA are shown in [**Table 1**](#T1){ref-type="table"}.

![The chemical structure of ferulic acid.](fphar-10-01298-g001){#f1}

###### 

Main pharmacokinetic parameters for ferulic acid, *Ginkgo biloba*, and resveratrol in humans.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Bioavail.\   *T* ~max~\   *T* ~1/2~\              Excretion                                                        References
                          (%)          (h)          (h)                                                                                      
  ----------------------- ------------ ------------ ----------------------- ---------------------------------------------------------------- -------------------
  Ferulic acid *per os*   20%          0.4--3       0.7--5                  Urine (glucuronide, sulfoglucuronide, and glycine metabolites)   ([@B71])

  *G. biloba*\            \> 80%       0.5--3       4--10                   Urine (40--70% unchanged)                                        ([@B46]; [@B105])
  ginkgolides\                                                                                                                               
  bilobalide\                                                                                                                                
  *per os*                                                                                                                                   

  ∼ 70%                   0.5--3       3--5         Urine (30% unchanged)                                                                    

  Resveratrol\                         1--1.5\      9--11                   Urine (monoglucuronide and sulfate metabolites)                  ([@B111])
  *per os*                             6\*                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Second peak probably due to the enteric recirculation of conjugate metabolites.

Bioavail., biovailability; T~max~, time to reach peak plasma concentration; T~1/2~, half-life.

Over the past years, several studies have shown that FA acts as a strong antioxidant not only by a direct free radical-scavenging mechanism, but largely by enhancing the cell stress response through the up-regulation of the HO/BVR system ([@B7]; [@B71]). On the other hand, literature data have highlighted the contribution of FA-induced HO-1 up-regulation to numerous biological effects in several preclinical models (see [**Table 2**](#T2){ref-type="table"}).

###### 

Contribution of HO-1 up-regulation to the biological effects of ferulic acid (FA) in preclinical *in vitro* and *in vivo* models.

  Preclinical model                          Ferulic acid\* (concentration or dose)   Effect(s)                                                             Reference(s)
  ------------------------------------------ ---------------------------------------- --------------------------------------------------------------------- --------------
  Radiation-induced damage in mice           50 mg/kg *per os* for 5 days             Prevention of radiation-induced oxidative damage in the duodenum      ([@B21])
  Cisplatin-induced nephrotoxicity in rats   50 mg/kg *per os* for 5 days             Prevention of drug-induced injury and improvement of renal function   ([@B6])
  Pre-adipocytes                             100 µM                                   Reduction of adipocyte tissue mass                                    ([@B47])
  Lymphocytes                                0.001--0.1 µM                            Inhibition of oxidative damage.                                       ([@B56])
  Endothelial cells                          0.2--5 µM                                Prevention of radiation-induced oxidative damage                      ([@B57])
  Melanocytes                                1--50 µM^†^                              Prevention of UVB-induced skin oxidative damage                       ([@B22])
  Rat heart                                  100 mg/kg *per os* for 14 days           Increase of the antioxidant defense in cardiac tissue                 ([@B120])
  Dermal fibroblasts                         25 µM^†^                                 Prevention of hydrogen peroxide-induced oxidative damage.             ([@B13])

\*Only studies carried out with purified FA or congeners have been included in this table.

^†^Ferulic acid ethyl ester.

UVB, ultraviolet B.

Ferulic acid and its ethyl ester \[5--50 µM or 150 mg/kg intraperitoneal (i.p.)\] were reported to over-express HO-1 in rat neurons and gerbil synaptosomes resulting in a significant neuroprotective effect on ROS- and glucose oxidase- related oxidative damage ([@B41]; [@B89]; [@B37]). In the neuronal cell line SH-SY5Y, FA (1--10 µM) exerted marked neuroprotective effects against trimethyltin-induced damage by increasing the expression of HO-1; the translocation of the transcriptional inducer nuclear factor erythroid 2-related factor 2 (Nrf2) from cytosol to the nucleus has been described as the molecular mechanism underlining the FA-induced HO-1 up-regulation ([@B15]). Moreover, CO and BR have been identified as the by-products of HO and BVR activities responsible for the antioxidant and neuroprotective effects of FA ([@B15]). Through the specific up-regulation of the Nrf2/HO-1 system, FA (3--30 µM) counteracted lead-induced inhibition of neurite outgrow in PC12 cells ([@B122]). As shown by Ma et al. ([@B56]), the extracellular signal-regulated kinase (ERK) has a role in mediating the FA-activation of Nrf2/HO-1 since its blockade counteracts the nuclear translocation and transcriptional activity of Nrf2 on the HO-1 gene. Quite recently, our research group has demonstrated how FA exerts neuroprotective effects not only under pro-oxidant conditions, but also during psychosocial stress. As shown by Mhillaj et al. ([@B75]), FA (150 mg/kg i.p.) enhances long-term memory in rats exposed to novelty-induced emotional arousal through the up-regulation of HO-1 in the hippocampus and frontal cortex; it is worth mentioning the finding that FA also over-expressed HO-2 in the frontal cortex. CO is responsible for this nootropic effect of FA, whereas BV does not have any significant effect ([@B75]).

Ferulic acid (150 mg/kg i.p. for 4 days) up-regulated HO-1 in the organ of Corti of guinea pigs exposed to acoustic trauma; FA-induced improvement of the auditory function was counteracted by the HO inhibitor zinc-protoporphyrin-IX and paralleled the time-course of FA-induced HO-1 overexpression, thus supporting the hypothesis that the neuroprotective effect of this phenolic acid was due to the induction of cytoprotective HO-1 ([@B25]). Interestingly, FA (21.61 mg/kg for 3 weeks intragastric) increased the HO-1 expression and counteracted visible light-induced retinal degeneration in pigmented rabbits ([@B113]).

Ferulic acid has also been complexed with tacrine, one of the earliest drugs developed for AD therapy and later discarded for severe hepatotoxicity. Tacrine-FA (2--100 µM) has been shown to prevent β-amyloid (Aβ) aggregation, ROS formation, and apoptosis in PC12 cells; in addition, tacrine-FA (2--20 mg/kg intragastric) improved cognitive skills in a mouse model of AD ([@B81]). In a subsequent paper, Huang et al. ([@B34]) showed how tacrine-FA inhibits oxidative stress-induced damage by over-expressing HO-1, through Nrf2 translocation, in HT22 cells.

Ferulic acid has an enviable safety profile, since no significant toxicities have been reported in humans; furthermore, FA's modulation of drug metabolizing enzymes is negligible (see <https://toxnet.nlm.nih.gov>. Accessed on June 27, 2019). However, female rats treated with the highest tolerated dose of tacrine-FA have shown both glycogen depletion and HO-1 induction and cytochrome-P450 (CYP) CYP1A1, 2B1, and 3A2 up-regulation in the liver, mainly due to the tacrine moiety ([@B54]). A careful risk/benefit analysis of the pharmacological and safety profiles of tacrine-FA is required.

*Ginkgo Biloba* {#s3}
===============

*Gingko biloba* is a plant growing in the mountainous valleys of Eastern China. *G. biloba* extracts contain several active compounds, including flavonoids, terpenes, organic acids, and polyphenols, the most important being flavonol-glycosides (primarily quercetin, kaempferol, and isorhamnetin) and terpene-lactones; the latter are further divided into diterpenes (ginkgolides) and sesquiterpenes (bilobalide) ([**Figure 2**](#f2){ref-type="fig"}). For a summary of the pharmacokinetic parameters and biological effects of *G. biloba*, see [**Tables 1**](#T1){ref-type="table"} and [**3**](#T3){ref-type="table"}, respectively.

![The chemical structure of ginkgolides and bilobalide.](fphar-10-01298-g002){#f2}

###### 

Contribution of HO-1 up-regulation to the biological effects of *Ginkgo biloba* in preclinical *in vitro* and *in vivo* models.

  Preclinical model                      *G. biloba* (concentration or dose)       Effect(s)                                                                                                                                                  Reference(s)
  -------------------------------------- ----------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------
  Myoblasts                              25--100 µg/mL                             Cytoprotection from alcohol-induced oxidative damage                                                                                                       ([@B109])
  Endothelial cells                      50--200 µg/mL                             Endothelial protection from high-glucose- or TNF-α--induced vascular oxidative damage; cytoprotection against cigarette smoke-induced apoptosis in lungs   ([@B32]; [@B17]; [@B102])
  Macrophages                            1--100 µg/mL                              Inhibition of inflammatory damage in LPS-treated cells; regulation of cholesterol homeostasis and reduction in atherosclerosis lesion size                 ([@B103]; [@B86])
  Ethanol-induced liver damage in rats   48 or 96 mg/kg intragastric for 90 days   Reduction of oxidative damage and improvement of ethanol-induced microvesicular steatosis and parenchimatous degeneration in hepatocytes                   ([@B119])

LPS, lipopolysaccharide; TNF, tumor necrosis factor.

Through the induction of HO-1, ginkgolides A, B, and C \[1, 3, and 10 mg/kg by intravenous route (i.v.)\] decreased neurological deficits and brain infarct volume in rats exposed to ischemia/reperfusion damage ([@B125]). In a similar experimental setting the *G. biloba* extract EGb 761 \[containing flavonol-glycosides (24%), ginkgolides A, B, and C (2.8--3.4%), and bilobalide (2.6--3.2%)\] at the dosage of 100 mg/kg *per os* for 7 days before or 4-24 h after damage reduced cortical infarct volume and stimulated the proliferation of neuronal stem/progenitor cells *via* HO-1 overexpression in mice with permanent middle cerebral artery occlusion ([@B94]; [@B76]; [@B77]). The same research group confirmed the neuroprotective effects of *G. biloba* in the hippocampus of mice pre-treated with EGb 761 (100 mg/kg *per os* for 7 days) and then susceptible to bilateral common carotid artery occlusion ([@B104]). The contribution of HO-1 to the neuroprotective effects of EGb 761 (100 mg/kg *per os*) was also demonstrated in HO-1 knockout male mice with middle cerebral artery occlusion ([@B87]). Ginkgolide B (1--50 µM or 10 mg/kg i.p.) prevented cisplatin-induced damage in HEI-OC1 auditory cells and rats through HO-1 induction ([@B55]). Interestingly, in order to improve brain penetration, *G. biloba* has been complexed with phosphatidylcholine ([@B14]); this novel formulation exhibited neuroprotective effects by increasing catalase, superoxide dismutase, glutathione peroxidase, and glutathione reductase activities in rat brain ([@B78]). Regrettably, there are no studies addressing the potential role of this novel formulation on HO-1. Worth mentioning is the nootropic effects of a novel formulation of *G. biloba* (120 mg/day *per os*) complexed with phosphatidylserine administered to healthy volunteers for 7 days ([@B43]).

As far as neurodegenerative disorders, no evidence has been found in literature dealing with the involvement of HO-1 and/or BVR in *G. biloba*-related neuroprotection. Indeed, the neuroprotective effects of EGb 761 have been extensively reported in both AD ([@B5]; [@B53]; [@B108]) or PD rodent models ([@B44]; [@B84]; [@B24]) and in humans. Over the last 2--3 years, some retrospective analyses, meta-analyses, and systematic reviews on the neurotherapeutic effects of *G. biloba* extracts in subjects with dementia, including AD, have been published and the conclusions are the following: (i) over 12 months treatment, EGb 761 and donepezil showed similar effects in cognitive decline in patients aged 80 years or older affected by AD ([@B82]); (ii) EGb 761 (240 mg/day *per os* for 22--24 weeks) had a better performance than placebo in 1,598 patients with dementia (probable AD with or without cerebrovascular disease and probable vascular dementia) ([@B88]); (iii) doses lower than 200 mg/day did not have any remarkable clinical effects in demented people ([@B123]) and (iv) *G. biloba* extract (240 mg/day *per os*) also showed neuroprotective effects in subjects with mild cognitive impairment ([@B124]; [@B40]). Unfortunately, there are no clinical studies on the neuroprotective effects of *G. biloba* in PD patients, therefore no conclusions can be drawn.

Although the safety profile of *G. biloba* extracts is acceptable, few mild adverse effects, including mild gastrointestinal complaints, headaches, and allergic reactions have been reported ([@B46]). However, important interactions between *G. biloba* and common drugs should be underlined. *G. biloba* is an inducer of CYP2C19 and, through this mechanism, it has been shown to reduce omeprazole plasma levels in individuals sharing the poor metabolizer phenotype ([@B121]) and to increase metabolism and reduce plasma concentrations of the antiepileptic drugs, valproic acid, and phenytoin, thus increasing the risk of fatal seizures ([@B49]). A greater risk of bleeding has been reported in people taking *G. biloba* and aspirin or warfarin ([@B1]). *G. biloba* has been discouraged in people taking selective serotonin-reuptake inhibitors for the increased risk of developing serotonin syndrome ([@B48]). Lastly, ginkgo flavonol-glycosides caused a coma in an 80-year-old AD patient taking trazodone, probably by stimulating the CYP3A4 activity which increases the transformation of trazodone into the active metabolite 1-(m-chlorophenyl) piperazine and up-regulates GABAergic activity in the brain ([@B27]).

Resveratrol {#s4}
===========

Resveratrol (3,5,4'-trihydroxy-*trans*-stilbene, ([**Figure 3**](#f3){ref-type="fig"}) is a phytoalexin found in grapes, cranberries, peanuts, and some beverages ([@B64]). However, wine is considered the main source of resveratrol since the solubility of the latter in ethanol is about 1,667-times higher than that in water ([@B115]). Also based on the interest aroused by the so-called "French paradox" over the last few years, the interaction resveratrol-HO-1 has been extensively studied for its beneficial effects in several preclinical models of disease ([**Table 4**](#T4){ref-type="table"}).

![The chemical structure of resveratrol.](fphar-10-01298-g003){#f3}

###### 

Contribution of HO-1 up-regulation to the biological effects of resveratrol in preclinical *in vitro* and *in vivo* models.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Preclinical model                Resveratrol (concentration or dose)         Effect(s)                                                                                                 Reference(s)
  -------------------------------- ------------------------------------------- --------------------------------------------------------------------------------------------------------- --------------------
  Kidney injury in rats            30 mg/kg i.p.                               Amelioration of sepsis-induced kidney injury                                                              ([@B112])

  Renal cells                      20 µM                                       Cytoprotection from nicotine-induced oxidative damage.                                                    ([@B3])

  Lung injury in rodents           30 mg/kg i.p.\                              Improvement of sepsis- or paraquat-induced lung injury in rats\                                           ([@B50]; [@B114])\
                                   1--3 mg/kg *per os* for 3 days              Enhancement of cell stress response and attenuation of cigarette smoke-induced damage in mice             ([@B52])

  Renal carcinoma in rats          30 mg/kg *per os* for 24 weeks              Inhibition of proliferation and improvement of renal function; increase in the antioxidant system         ([@B39])

  Membranous nephropathy in mice   30 mg/kg s.c. every other day for 6 weeks   Reduction of apoptosis and complement-induced damage; amelioration of renal function                      ([@B116])

  Endothelial cells                0.01--10 µM                                 Reduction of oxidative stress-induced damage and inhibition of senescence in progenitor cells             ([@B96])

  Smooth muscle cells              1--10 µM                                    Inhibition of oxidative damage and inflammation; vascular protection                                      ([@B38])

  Obstructive jaundice in rats     10--20 mg/kg *per os*                       Restoration of intestinal permeability and improvement of gut barrier function                            ([@B110])

  Gastric inflammation in mice     100 mg/kg *per os* for 6 weeks              Reduction of oxidative damage and inflammation in *Helicobacter pylori*--infected gastric mucosa          ([@B126])

  Myocardial damage in rats        100 µM i.v.                                 Reduction of oxidative damage and improvement of cardiac function following ischemia/reperfusion injury   ([@B18])

  Hepatoma cells                   1 µM                                        Stimulation of mitochondrial biogenesis and reduction of inflammatory damage                              ([@B45])

  Macrophages                      1--10 µM                                    Inhibition of inflammatory damage                                                                         ([@B99])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

i.p., intraperitoneal route of administration; i.v., intravenous route of administration; s.c., subcutaneous route of administration.

With regard to the neuroprotective effects, earlier studies showed that resveratrol (5--100 µM) up-regulates HO-1 in primary cultures of mouse neurons ([@B127]). Resveratrol (15 µM), was also found to increase HO-1 expression in neuron-like PC12 cells through both phosphoinositide 3-kinase and MEK1/2 activities ([@B16]). Quite recently, resveratrol (10 µM) has exhibited a marked protective effect on primary rat oligodendrocyte progenitor cells exposed to lipopolysaccharide through the modulation of Nrf2/HO-1 pathway and the enhancement of cell stress response ([@B85]). Neuroprotective effects, due to HO-1 up-regulation, have also been shown in C6 astroglial cells and in hippocampal primary rat astrocytes treated with 100 µM resveratrol and then exposed to neurotoxicants, such as buthionine sulfoximine, azide, or ammonia, for 3--24 h ([@B11]; [@B9]; [@B4]).

Resveratrol (20--40 mg/kg i.p. for 7 days) significantly enhanced HO-1 expression and prevented both cerebral edema and infarction in seven-day-old rat pups exposed to hypoxic/ischemic injury secondary to unilateral carotid artery ligation ([@B28]). Similar results have been obtained in adult male rats treated with resveratrol (15--30 mg/kg i.p. for 7 days) and undergoing middle cerebral artery occlusion; in these animals, HO-1 induction was paralleled by down-regulation of caspase-3 and improvement of neuronal viability ([@B83]). Resveratrol (1--100 µM) increased HO-1 expression in both rat neural stem cells and primary rat cortical neurons exposed to glucose deprivation/reoxygenation injury (an *in vitro* experimental model mimicking cerebral artery occlusion and reperfusion injury) along with a strong enhancement of cell stress response and a marked reduction of apoptotic cell death ([@B95]; [@B118]). As far as AD is concerned, resveratrol (10--40 µM) has been shown to counteract Aβ-induced oxidative stress in PC12 cells through the overexpression of Nrf2/HO-1 system ([@B35]). In Aβ-treated rats, resveratrol \[100 µM/5 µL by intracerebroventricular route (i.c.v.)\] up-regulated hippocampal HO-1, reduced neuronal death in the same area, and improved spatial memory ([@B33]). In SH-SY5Y cells exposed to rotenone, resveratrol (10--20 µM) induced HO-1 expression and prevented dopaminergic cell death by autophagy ([@B51]).

Studies in humans have found that resveratrol (25 mg *per os*) has a low bioavailability and reaches plasma concentrations of about 40 nM within 2 h from administration ([@B31]; [@B107]); plasma concentrations up to 2.4 µM are reached if the dose of resveratrol increases up to 1 g ([@B2]). For a summary of resveratrol pharmacokinetics see [**Table 1**](#T1){ref-type="table"}. In order to improve bioavailability, resveratrol has been complexed with solid lipid nanoparticles (SLN) or gold-conjugated nanoparticles ([@B80]; [@B117]). Among these formulations, SLN increased by about 4-times the brain levels of resveratrol, which was able to up-regulate HO-1 and improve cognitive decline in rats with permanent bilateral common carotid artery occlusion ([@B117]). Unfortunately, there are no studies in humans on the effective concentrations of resveratrol in the brain and a brain concentration greater than 2.4 µM is unlikely, by considering the plasma concentrations reached in the studies mentioned above and the presence of the blood-brain barrier. This suggests that most of the preclinical studies on the neuroprotective effects of resveratrol cannot be applied to humans. As far as the role of wine as the source of resveratrol is concerned, considering both the annual consumption of red and white wines in France (31.7 vs 11.7 L, respectively) and the amount of resveratrol contained in red and white wines (2 and 0.5 mg/L, respectively), it is possible to calculate an amount of resveratrol "drunk" of about 0.2 mg/day, 5000-times less than the highest daily dosage (1 g/day) claimed to give rise to pharmacological effects ([@B115]).

It is worth mentioning the document released by the EFSA regarding the request by the European Commission on the safety of trans-resveratrol as a novel food ([@B23]). In this document, the EFSA established that the 38 clinical studies provided in support of the claim do not lead to any conclusion about the efficacy of resveratrol, at doses up to 5 g/day for either acute (4 days) or chronic administration (4--12 weeks), in the treatment of metabolic diseases or cancer. The EFSA pointed out the heterogeneity of the resveratrol doses, the low number of individuals recruited, the uncontrolled experimental design, and the exploratory character of several studies.

In some clinical studies, patients supplemented with resveratrol reported mild adverse effects, such as diarrhea and hot flushes. As far as the interaction with drugs-metabolizing enzymes is concerned, resveratrol has been shown to inhibit CYP3A4, CYP2D6, and CYP2C9 and to induce CYP1A2 *in vitro*. No significant changes in plasma levels of common drugs have been reported so far ([@B23]).

Conclusions {#s5}
===========

In illustrating the interactions between the HO/BVR system with FA, *G. biloba*, and resveratrol, we have attempted to address some critical points presented in the Introduction, discussing each issue to the best of our knowledge.

An initial consideration concerns the janus face of the HO-1/BVR by-products. As mentioned in the Introduction, both CO and BR have important pleiotropic and neuroprotective effects in the nervous system, but they may become toxic in the case of a disproportionate production or under conditions of redox imbalance ([@B70]; [@B67]; [@B62]). The potential toxic effect due to an over activation of the HO/BVR system has also been supported by the discovery of the importance of HO-1 gene repression in order to preserve cell homeostasis and integrity ([@B97]; [@B98]; [@B79]). For this reason, the long-lasting induction of HO-1 due to chronic supplementation with herbal products may be a double-edged sword and the possibility of neurotoxicity must be carefully considered.

Regarding the effective dose correlation *in vitro* and blood or tissue concentrations found *in vivo*, resveratrol is an indisputable example. Both the bioavailability data through wine consumption and the EFSA opinion on anti-inflammatory efficacy do not justify the turmoil often generated by the media regarding the beneficial properties of resveratrol in red wine. In this regard, the antioxidant, antithrombotic, and metabolic effects of ethanol *per se* often are not mentioned; moreover, red wines usually contain ethanol in greater concentration than white wines and the beneficial effects claimed for the former can be due, once again, to ethanol ([@B30]; [@B20]; [@B10]). Focusing on the beneficial effects of moderate ethanol consumption would also allow a greater responsibility on the consumers' part towards their own health, because of the pathological effects of uncontrolled alcohol intake are well known. On the contrary, if attention is focused on resveratrol, of which only the beneficial effects are artificially advertised, the need for a controlled intake of red wine is lost since the attention is driven towards a natural compound.

The risk linked to the effects on drug metabolizing enzymes and the health consequences in case of concomitant drug intake, concepts that are very often neglected also by health professionals, should be emphasized. Particularly dangerous are the interactions between *G. biloba* and CYP or other phase II enzymes, which could increase the risk of toxicity in patients treated with drugs, such as valproic acid, trazodone, talinolol, warfarin, etc. It is worth mentioning that the lack of reliable data on the neuroprotective effects of resveratrol and *G. biloba* challenges their potential beneficial effects in the treatment of neurodegenerative diseases. In this regard, more attention is required for FA for which, to our knowledge, there are no clinical studies confirming the promising neuroprotective results obtained on preclinical models. The few clinical studies available, addressing the kinetics in most cases, have been performed using foods rich in FA and this does not always allow to ascertain the actual dose administered and any confounding effects related to other active compounds present. Actually, only one randomized and double-blind study on hyperlipidemic patients ([@B12]) has appeared in the literature and shows the hypolipemic, anti-inflammatory, and antioxidant effects of FA (1 g/day *per os* for 6 weeks).

These considerations lead to the conclusion that there is not sufficient evidence on the efficacy of these herbal products in neurodegenerative diseases and that further efforts and many attempts are recommended and requested by doctors, researchers, and other health professionals to bridge this gap for the benefit of patients and their families.
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